Intellia Therapeutics received a share upgrade from William Blair, while Bank of America reiterated a neutral rating on June 17, 2026.

The entities involved

• Intellia Therapeutics →

  It is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system.

  • Intellia Therapeutics and Neurogene are identified as small-cap healthcare companies.08:13
  • Intellia Therapeutics and BeyondSpring are identified as small-cap healthcare companies.Mon 05:20
• William P. Blair →

  American astrophysicist

  • William Blair analysts are monitoring the ongoing G20 meetings.Fri 23:06
  • Jefferies Financial Group initiated coverage of Suja Life, Inc., providing a buy rating and price objective as of July 18, 2026.Sun 05:23
• Bank of America →

  American multinational banking and financial services corporation

  • Phillip Kim assists in a class action lawsuit against Bank of America.12:29
  • Amundi and Bank of America increased their positions in Microsoft shares, with filings tracked by the SEC.08:52

Related events

• Intellia Therapeutics and Spyre Therapeutics, Inc. are identified as healthcare companies competing for investment.Mon 04:25
• Intellia Therapeutics and BeyondSpring Inc. are identified as small-cap healthcare companies.Mon 05:20
• William Blair upgraded shares of Beam Therapeutics to strong-buy, while Bank of America reaffirmed its buy rating. Amy Simon also sold shares.Oct 6